http://stroke.ahajournals.org/content/46/10/2853.abstract?sid=11c952b2-13f1-4c37-8bf6-06699a5d6f8a
- Sohail M. Mulla, MSc;
- Li Wang, PhD;
- Rabia Khokhar, MScOT;
- Zain Izhar, BSc (Hons);
- Arnav Agarwal, BHSc;
- Rachel Couban, MISt;
- D. Norman Buckley, MD;
- Dwight E. Moulin, MD;
- Akbar Panju, MD;
- Sun Makosso-Kallyth, PhD;
- Alparslan Turan, MD;
- Victor M. Montori, MD;
- Daniel I. Sessler, MD;
- Lehana Thabane, PhD;
- Gordon H. Guyatt, MD;
- Jason W. Busse, PhD
+ Author Affiliations
- Correspondence to Sohail M. Mulla, MSc, Department of Clinical Epidemiology and Biostatistics, HSC-2C7, McMaster University, 1280 Main St W, Hamilton, Ontario L8S 4K1, Canada. E-mail mullasm@mcmaster.ca
Abstract
Background and Purpose—Central poststroke pain is a chronic neuropathic disorder that follows a stroke. Current research on its management is limited,
and no review has evaluated all therapies for central poststroke pain.
Methods—We
conducted a systematic review of randomized controlled trials to
evaluate therapies for central poststroke pain. We identified
eligible trials, in any language, by
systematic searches of AMED, CENTRAL, CINAHL, DARE, EMBASE, HealthSTAR,
MEDLINE, and
PsychINFO. Eligible trials (1) enrolled ≥10
patients with central poststroke pain; (2) randomly assigned them to an
active
therapy or a control arm; and (3) collected
outcome data ≥14 days after treatment. Pairs of reviewers, independently
and in
duplicate, screened titles and abstracts of
identified citations, reviewed full texts of potentially eligible
trials, and
extracted information from eligible studies.
We used a modified Cochrane tool to evaluate risk of bias of eligible
studies,
and collected patient-important outcomes
according to recommendations by the Initiative on Methods, Measurement,
and Pain
Assessment in Clinical Trials. We conducted,
when possible, random effects meta-analyses, and evaluated our certainty
in treatment
effects using the Grading of Recommendations
Assessment, Development, and Evaluation System.
Results—Eight
eligible English language randomized controlled trials (459 patients)
tested anticonvulsants, an antidepressant, an
opioid antagonist, repetitive transcranial
magnetic stimulation, and acupuncture. Results suggested that all
therapies had
little to no effect on pain and other
patient-important outcomes. Our certainty in the treatment estimates
ranged from very
low to low.
Conclusions—Our findings are inconsistent with major clinical practice guidelines; the available evidence suggests no beneficial effects
of any therapies that researchers have evaluated in randomized controlled trials.
No comments:
Post a Comment